BioStock: Dicot initiates repeated dosing in phase I study

Dicot recently entered phase I with its drug candidate LIB-01, where the first step is to test single dosing on healthy volunteers. In parallel, the company is now starting the second part of the study, testing repeated dosing of the candidate. The first results from the study are expected in the spring.

Read the full article at biostock.se:

https://www.biostock.se/en/2023/10/dicot-initiates-repeated-dosing-in-phase-i-study/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se